A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)

阿替唑单抗 医学 肿瘤科 宫颈癌 内科学 泌尿科 癌症 免疫疗法 无容量
作者
Ritu Salani,Mary McCormack,Yong‐Man Kim,Sharad Ghamande,Shaundra L. Hall,Domenica Lorusso,Lisa Barraclough,Lucy Gilbert,Adrian Guzman Ramirez,Chien‐Hsing Lu,Renaud Sabatier,Nicoletta Colombo,Youyou Hu,Venkatesh Krishnan,Luciana Molinero,Yuning Feng,Nicole J. Kim,Marcela Castro,Yvonne G. Lin,Bradley J. Monk
出处
期刊:International Journal of Gynecological Cancer [BMJ]
卷期号:34 (8): 1140-1148 被引量:21
标识
DOI:10.1136/ijgc-2024-005588
摘要

Objective

To evaluate tiragolumab (anti-TIGIT) and atezolizumab (anti-PD-L1) as second- or third-line therapy for PD-L1-positive persistent/recurrent cervical cancer.

Methods

In the open-label, non-comparative, randomized phase II SKYSCRAPER-04 trial (NCT04300647), patients with PD-L1-positive (SP263 tumor area positivity ≥5%) recurrent/persistent cervical cancer after 1–2 chemotherapy lines (≥1 platinum-based) were randomized 3:1 to atezolizumab 1200 mg with/without tiragolumab 600 mg every 3 weeks until disease progression or unacceptable toxicity. Stratification factors were performance status, prior (chemo)radiotherapy, and disease status. The primary endpoint was independent review committee-assessed confirmed objective response rate per RECIST v1.1 in patients receiving tiragolumab plus atezolizumab. An objective response rate ≥21% (one-sample z-test p≤0.0245) was required for statistical significance versus a historical reference.

Results

Protocol-defined independent review committee-assessed objective response rates were 19.0% (95% CI 12.6 to 27.0) in 126 patients receiving tiragolumab plus atezolizumab (p=0.0787 vs historical reference) and 15.6% (95% CI 6.5 to 29.5) in 45 atezolizumab-treated patients. Response rates were higher in PD-L1high (tumor area positivity ≥10%) than PD-L1low (tumor area positivity 5%–9%) subgroups with both regimens. At 8.5 months' median follow-up, independent review committee-assessed progression-free survival was 2.8 months (95% CI 1.7 to 4.1) with tiragolumab plus atezolizumab and 1.9 months (95% CI 1.5 to 3.0) with atezolizumab. In post hoc analyses (10.4 months' median follow-up), median overall survival was 11.1 months (95% CI 9.6 to 14.5) with the combination and 10.6 months (95% CI 6.9 to 13.8) with atezolizumab (crossover permitted). In the combination group, 3% of patients had adverse events requiring treatment discontinuation and 8% had grade ≥3 adverse events of special interest; corresponding values in the single-agent arm were 4% and 11%. There were no treatment-related deaths or new safety findings.

Conclusion

The objective response rate with the tiragolumab-plus-atezolizumab combination was numerically higher than the historical reference but did not reach statistical significance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
余香的应助被chc采纳,获得10
1秒前
2秒前
2秒前
2秒前
2秒前
风吹麦浪的应助被PennPeak采纳,获得10
2秒前
冷静新柔完成签到,获得积分10
2秒前
水煮电吹风的应助被任性山芙采纳,获得10
3秒前
cdercder的应助被任性山芙采纳,获得10
3秒前
3秒前
toot完成签到,获得积分10
4秒前
4秒前
韩晓蕊完成签到,获得积分10
4秒前
5秒前
6秒前
彭于晏的应助被张君采纳,获得10
6秒前
fdl完成签到 ,获得积分10
6秒前
7秒前
哈哈王完成签到,获得积分10
7秒前
落骛发布了新的文献求助30
7秒前
NexusExplorer的应助被吴军霄采纳,获得10
7秒前
7秒前
海哥哥发布了新的文献求助10
8秒前
8秒前
8秒前
YixiaoWang完成签到,获得积分10
9秒前
今后的应助被youkang采纳,获得10
9秒前
tao完成签到,获得积分10
9秒前
9秒前
泽北发布了新的文献求助10
10秒前
长青发布了新的文献求助10
10秒前
周舟完成签到,获得积分10
11秒前
hyl完成签到,获得积分10
11秒前
李健的应助被布洛芬采纳,获得10
11秒前
11秒前
徐枘发布了新的文献求助10
11秒前
13秒前
晶晶完成签到,获得积分0
13秒前
369ninja发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817